JP2021095371A - Skin external preparation and internal preparation - Google Patents
Skin external preparation and internal preparation Download PDFInfo
- Publication number
- JP2021095371A JP2021095371A JP2019228336A JP2019228336A JP2021095371A JP 2021095371 A JP2021095371 A JP 2021095371A JP 2019228336 A JP2019228336 A JP 2019228336A JP 2019228336 A JP2019228336 A JP 2019228336A JP 2021095371 A JP2021095371 A JP 2021095371A
- Authority
- JP
- Japan
- Prior art keywords
- heat treatment
- dry heat
- extract
- subjected
- buds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000010438 heat treatment Methods 0.000 claims abstract description 74
- 239000000284 extract Substances 0.000 claims abstract description 56
- 241000234435 Lilium Species 0.000 claims abstract description 32
- 102000007000 Tenascin Human genes 0.000 claims abstract description 31
- 108010008125 Tenascin Proteins 0.000 claims abstract description 31
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 claims abstract description 18
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims abstract description 18
- 230000037319 collagen production Effects 0.000 claims abstract description 10
- 230000037303 wrinkles Effects 0.000 claims description 23
- 241000234280 Liliaceae Species 0.000 claims description 22
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 26
- 239000001301 oxygen Substances 0.000 abstract description 26
- 229910052760 oxygen Inorganic materials 0.000 abstract description 26
- 230000001737 promoting effect Effects 0.000 abstract description 15
- 230000002000 scavenging effect Effects 0.000 abstract description 13
- 239000002537 cosmetic Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000009759 skin aging Effects 0.000 abstract description 5
- 230000006866 deterioration Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 230000003796 beauty Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000004615 ingredient Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 239000000469 ethanolic extract Substances 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 12
- -1 Longiflorum hybrid Species 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- 239000003205 fragrance Substances 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000012422 Collagen Type I Human genes 0.000 description 7
- 108010022452 Collagen Type I Proteins 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229940058015 1,3-butylene glycol Drugs 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 235000019437 butane-1,3-diol Nutrition 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 238000007665 sagging Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003763 carbonization Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 2
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000001117 keloid Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000009757 Browns lily Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001648859 Lilium candidum Species 0.000 description 1
- 244000210789 Lilium lancifolium Species 0.000 description 1
- 235000002156 Lilium lancifolium Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000005995 skin dysfunction Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Landscapes
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、新規な老化防止作用に優れた皮膚外用剤、テネイシンC発現促進剤、コラーゲン産生促進剤、MMP1阻害剤、活性酸素消去剤、シワ改善剤及び内用剤に関する。 The present invention relates to a novel external preparation for skin having an excellent antiaging effect, a tenascin C expression promoter, a collagen production promoter, an MMP1 inhibitor, an active oxygen scavenger, a wrinkle improver and an internal preparation.
テネイシンC(TNC)は細胞外マトリックスの糖タンパク質の一つであり、胎生期や組織のリモデリングの際に発現する。結合組織や瘢痕に、フィブロネクチンが接着分子として働く際に関係する分子で、TNCは正常な成人ではほとんど発現しないが、創傷治癒等の特殊な状態下においては再びその間質に発現する、時期及び場所特異性を有する細胞外マトリックスの一つである。細胞接着を抑制し細胞遊走、分化、分裂やアポトーシスを誘導することで形態形成、創傷治癒に役割を果たしているものと考えられる。正常皮膚では、基底膜上と表皮−真皮結合間にしか発現がないのに対して、ケロイドでは真皮網状層のコラーゲン線維に沿ってTNCの発現が増加する。ケロイド組織におけるTNCのmRNA発現レベルは、正常皮膚に比べて有意に上昇していることが報告されている(非特許文献1)。 Tenascin C (TNC) is one of the extracellular matrix glycoproteins and is expressed during embryonic period and tissue remodeling. A molecule involved in fibronectin acting as an adhesion molecule in connective tissue and scars. TNC is rarely expressed in normal adults, but is re-expressed in the interstitial space under special conditions such as wound healing. It is one of the extracellular matrix having specificity. It is thought to play a role in morphogenesis and wound healing by suppressing cell adhesion and inducing cell migration, differentiation, division and apoptosis. In normal skin, expression is only on the basement membrane and between the epidermis-dermis junction, whereas in keloids, TNC expression is increased along the collagen fibers of the dermis reticular layer. It has been reported that the TNC mRNA expression level in keloid tissues is significantly higher than that in normal skin (Non-Patent Document 1).
又、関節軟骨においても、TNCは成長過程で発現が増加し、軟骨細胞の成熟に伴い発現が減少し、最終的には正常の成人関節軟骨では発現が消失する。しかし、変形性関節症や関節リウマチといった病的な関節軟骨や滑膜においては、TNCが再発現することから、TNCは軟骨の修復に有用であることが示唆されている。又、マウスにTNCを投与した実験では、TNCによる軟骨変性抑制効果が報告されている(非特許文献2)。以上のことから、TNCの投与及びTNCの発現低下の抑制は、創傷治癒や変形軟骨関節症・関節リウマチの予防及び治療に有効である。 Also, in articular cartilage, the expression of TNC increases in the growth process, decreases with the maturation of chondrocytes, and finally disappears in normal adult articular cartilage. However, in pathological articular cartilage and synovium such as osteoarthritis and rheumatoid arthritis, TNC is re-expressed, suggesting that TNC is useful for cartilage repair. Further, in an experiment in which TNC was administered to mice, the effect of suppressing cartilage degeneration by TNC has been reported (Non-Patent Document 2). From the above, administration of TNC and suppression of decreased expression of TNC are effective for wound healing and prevention and treatment of osteoarthritis of the cartilage and rheumatoid arthritis.
皮膚は、紫外線、乾燥、寒冷、熱、薬物等の様々な物理的及び化学的ストレスに日々曝されている。その結果、皮膚の機能低下が引き起こされ、様々な皮膚の老化現象が顕在化する。皮膚の老化現象の一つにシワがある。シワには、表皮性のシワと、真皮性のシワの二種類が存在することが知られている。表皮性のシワは小ジワと呼ばれ、皮膚の乾燥により、表皮角質中の水分量が低下することによって一時的に生じるシワである。一方、真皮性のシワは、太陽光線に含まれる紫外線や加齢によって形成されるシワである。その形成メカニズムとしては、紫外線や加齢による真皮線維芽細胞におけるコラーゲン合成能の低下や、マトリックスメタロプロテアーゼ(MMP)の増加によるコラーゲンの分解促進が挙げられる。 The skin is exposed daily to various physical and chemical stresses such as UV light, dryness, cold, heat and drugs. As a result, skin dysfunction is caused, and various skin aging phenomena become apparent. Wrinkles are one of the skin aging phenomena. It is known that there are two types of wrinkles, epidermal wrinkles and dermal wrinkles. Epidermal wrinkles are called fine wrinkles, which are temporary wrinkles caused by a decrease in the amount of water in the epidermal keratin due to dry skin. On the other hand, dermal wrinkles are wrinkles formed by ultraviolet rays contained in the sun's rays and aging. The formation mechanism includes a decrease in collagen synthesis ability in dermal fibroblasts due to ultraviolet rays and aging, and an increase in matrix metalloproteinase (MMP) to promote collagen degradation.
乾燥に起因する表皮性のシワと真皮性のシワでは、組織学的形態、発症メカニズム、治療方法が異なり、紫外線や加齢により生じる真皮性のシワは、保湿効果を有する化粧品の使用によって改善することは困難である。 Epidermal wrinkles caused by dryness and dermal wrinkles have different histological morphology, onset mechanism, and treatment method, and dermal wrinkles caused by ultraviolet rays and aging are improved by using cosmetics having a moisturizing effect. That is difficult.
これまでに、紫外線によって生じる真皮性のシワを改善することを目的として、加水分解アーモンドを有効成分とする皮膚のシワ形成防止・改善剤(特許文献1)、ジョチョウケイ、テンキシ及びキセンウの抽出物を有効成分とする紫外線照射に起因するシワの改善剤(特許文献2)が報告されている。 So far, for the purpose of improving dermal wrinkles caused by ultraviolet rays, an agent for preventing / improving skin wrinkles containing hydrolyzed almond as an active ingredient (Patent Document 1), extracts of Jochokei, Tenxi and Kisenu. An agent for improving wrinkles caused by irradiation with ultraviolet rays containing the active ingredient (Patent Document 2) has been reported.
又、真皮には線維芽細胞やコラーゲンが存在し、I型コラーゲンが全体の80%を占める。I型コラーゲンの他には、III、V、XII及びXIV型コラーゲンの存在が知られている。シワやたるみの原因の一つとして、I型コラーゲンの減少が挙げられる。従って、I型コラーゲンの産生を促進させることがシワ・たるみの予防・改善に有効であると考えられる。又、I型コラーゲンの産生促進は皮膚の創傷治癒の改善にも有効である。 In addition, fibroblasts and collagen are present in the dermis, and type I collagen accounts for 80% of the total. In addition to type I collagen, the presence of type III, V, XII and XIV collagen is known. One of the causes of wrinkles and sagging is a decrease in type I collagen. Therefore, it is considered that promoting the production of type I collagen is effective in preventing and improving wrinkles and sagging. In addition, promotion of type I collagen production is also effective in improving skin wound healing.
又、コラーゲンは、哺乳動物組織の約1/3を占める主要な構造タンパク質であり、軟骨、骨、腱、及び皮膚等の、多くのマトリックス組織の必須な成分である。MMPに属するコラゲナーゼ(MMP1)により一箇所を切断されると、通常の組織内では安定なコラーゲン分子は変性して一本鎖のゼラチンとなり、他の様々なプロテアーゼにより分解されるようになる。その結果、マトリックス組織の構造の完全性が失われてしまう。 Collagen is a major structural protein that occupies about one-third of mammalian tissues and is an essential component of many matrix tissues such as cartilage, bone, tendons, and skin. When one site is cleaved by collagenase (MMP1) belonging to MMP, stable collagen molecules in normal tissues are denatured into single-stranded gelatin, which is decomposed by various other proteases. As a result, the structural integrity of the matrix structure is lost.
コラゲナーゼの阻害活性を有する素材として、例えば、カカオ豆皮であるカカオハスク抽出物(特許文献3)、バラ科オニイチゴ抽出物(特許文献4)、ラクトフェリン(特許文献5)等が提案されている。皮膚老化や口腔衛生にますます関心が高まっている状況下で、副作用がなく、安全性が高い、コラゲナーゼ活性阻害作用の優れた素材を見出すことが求められている。 As a material having an inhibitory activity on collagenase, for example, cacao husk extract (Patent Document 3), Rosaceae onistrawberry extract (Patent Document 4), lactoferrin (Patent Document 5), which is cacao bean bark, and the like have been proposed. Under the increasing interest in skin aging and oral hygiene, it is required to find a material having no side effects, high safety, and excellent collagenase activity inhibitory action.
又、線維芽細胞はコラーゲン等のタンパク質及びヒアルロン酸等のグリコサミノグリカンを産生して真皮結合組織を形成し、皮膚のハリを保っている。この結合組織が収縮力を失い、さらに弾力性を失う結果として皮膚のシワやたるみが発生すると考えられている。 In addition, fibroblasts produce proteins such as collagen and glycosaminoglycans such as hyaluronic acid to form dermis connective tissue and maintain the firmness of the skin. It is believed that this connective tissue loses its contractile force and further loses its elasticity, resulting in wrinkles and sagging of the skin.
皮膚は生体の最外層に位置し、紫外線等の影響により活性酸素が発生しやすい臓器であり、絶えずその酸素ストレスに曝されている。一方、皮膚細胞内には活性酸素消去酵素が存在しており、その能力を超える活性酸素が発生しないかぎり活性酸素の傷害から皮膚細胞を防衛している。ところが、皮膚細胞内の活性酸素消去酵素の活性は加齢と共に低下することが知られており、活性酸素による傷害がその防御反応を凌駕したとき、皮膚は酸化され、細胞機能が劣化して老化が進行すると考えられる。又、皮膚以外の臓器においても、その活性酸素消去能を越える活性酸素に曝されたとき、機能低下が起こり老化したり、ガンや心筋梗塞等様々な生活習慣病が発症したりすると考えられる。 The skin is located in the outermost layer of the living body, and is an organ that easily generates active oxygen due to the influence of ultraviolet rays and the like, and is constantly exposed to the oxygen stress. On the other hand, active oxygen scavenging enzyme exists in the skin cell and protects the skin cell from the damage of the active oxygen unless the active oxygen exceeding its capacity is generated. However, it is known that the activity of active oxygen scavenging enzyme in skin cells decreases with aging, and when the damage caused by active oxygen exceeds the defense reaction, the skin is oxidized, the cell function deteriorates and aging. Is thought to progress. In addition, it is considered that when an organ other than the skin is exposed to active oxygen exceeding its active oxygen scavenging ability, functional deterioration occurs and aging occurs, and various lifestyle-related diseases such as cancer and myocardial infarction develop.
近年、生体内における活性酸素の生成とそれによって起こる様々な影響が報告されている。一般的に、この活性酸素はActivated oxygensと呼ばれ、O2 −、H2O2、・OH、1O2の4種に大別され、いずれも強力な殺菌作用を有し、生体の自己防衛に関与する重要な物質と捉えられている。例えば、細菌・ウイルス、異物等、抗原となるものが生体内に侵入すると、まず血液中の食細胞である好中球・単球・マクロファージが貪食作用を開始し、次に、食細胞の胞体中に貪食された異物類を溶解するために活性酸素が生産される。そして、生産された活性酸素は貪食物の溶解にあたる他、一方では、直接的に細菌・ウイルスや異物等の外敵に対して殺菌作用を及ぼし、外敵から防御する役割を果たしている。 In recent years, the production of active oxygen in the living body and various effects caused by it have been reported. Generally, the active oxygen is called Activated oxygens, O 2 -, H 2 O 2, is divided into four · OH, 1 O 2, both have a strong bactericidal action, the biofeedback It is regarded as an important substance involved in defense. For example, when an antigen such as a bacterium, a virus, or a foreign substance invades a living body, neutrophils, monocytes, and macrophages, which are phagocytic cells in the blood, first start phagocytic action, and then phagocyte vesicles. Reactive oxygen species are produced to dissolve the foreign substances that have been phagocytosed inside. The produced active oxygen not only dissolves greedy foods, but also directly exerts a bactericidal action on foreign enemies such as bacteria, viruses and foreign substances, and plays a role of protecting against foreign enemies.
しかしながら、この自己防衛のための活性酸素も過剰に生産されると、正常な細胞までも刺激を受けることとなり、様々な傷害反応をもたらしてしまう。最近では、活性酸素によって誘発される疾患も数多く報告されている。そこで、活性酸素による傷害からの防御を目的として活性酸素消去剤や抗酸化剤が検討され、SODやカタラーゼ等の活性酸素消去酵素、SOD様活性物質等の活性酸素消去剤や抗酸化剤を含有した食品、化粧品、医薬部外品及び医薬品等が開発されている(特許文献6、7)。 However, if the active oxygen for self-defense is also excessively produced, even normal cells will be stimulated, resulting in various injury reactions. Recently, many diseases induced by active oxygen have been reported. Therefore, active oxygen scavengers and antioxidants have been studied for the purpose of protection from damage caused by active oxygen, and contain active oxygen scavengers such as SOD and catalase, and active oxygen scavengers and antioxidants such as SOD-like active substances. Foods, cosmetics, non-pharmaceutical products, pharmaceuticals, etc. have been developed (Patent Documents 6 and 7).
乾式加熱処理とは、素材に水を使用せずに熱を加える方法を指す。一般的には、乾式加熱処理によってタンパク質等の化学成分に変化が生じるとされていて、色味や味、香り等を変化させることが可能である。加熱する温度や時間によっても、化学成分の変化には違いが生じる。 Dry heat treatment refers to a method of applying heat to a material without using water. Generally, it is said that a dry heat treatment causes a change in a chemical component such as a protein, and it is possible to change the color, taste, aroma, and the like. The change in chemical composition also differs depending on the heating temperature and time.
従来、ユリ科ユリ属の植物の花部、葉部の抽出物が保湿、肌荒れ改善の効果を有し、抗老化有効成分として化粧料に含有されること(特許文献8、9)や、ユリ科ユリ属の植物の花部の抽出物がメラニン生成抑制効果を有し、美白有効成分として化粧料に含有されること(特許文献10)、ユリ科ユリ属の蕾部の抽出物が活性酸素消去作用を有することが知られている(特許文献11)。しかしながら、ユリ科ユリ属の蕾部に乾式加熱処理を施すことで、乾式加熱処理を施していないユリ科ユリ属の蕾部と比べて、顕著なTNC発現促進作用、コラーゲン産生促進作用、MMP1阻害作用及び活性酸素消去作用を示すことは知られていなかった。 Conventionally, extracts of flowers and leaves of plants belonging to the genus Lily of the Liliaceae family have the effects of moisturizing and improving rough skin, and are contained in cosmetics as an anti-aging active ingredient (Patent Documents 8 and 9), and lilies. The extract of the flower part of the plant of the genus Liliaceae has the effect of suppressing melanin production and is contained in cosmetics as a whitening active ingredient (Patent Document 10), and the extract of the bud part of the genus Lily of the family Liliaceae is active oxygen. It is known to have an erasing action (Patent Document 11). However, by applying the dry heat treatment to the buds of the genus Lily of the Liliaceae family, the buds of the genus Lily of the Liliaceae family, which are not subjected to the dry heat treatment, have a remarkable TNC expression promoting action, collagen production promoting action, and MMP1 inhibition. It was not known to have an action and an active oxygen scavenging action.
安全で安定性に優れ、テネイシンC発現促進作用、コラーゲン産生促進作用、MMP1阻害作用及び活性酸素消去作用に優れた素材が望まれているが、未だ十分満足し得るものが提供されていないのが現状である。 Materials that are safe, have excellent stability, and have excellent tenascin C expression-promoting action, collagen production-promoting action, MMP1 inhibitory action, and active oxygen scavenging action have been desired, but materials that are sufficiently satisfactory have not yet been provided. The current situation.
このような事情により、本発明者らは鋭意検討した結果、乾式加熱処理を行ったユリ科ユリ属の蕾部の抽出物が優れたテネイシンC発現促進作用、コラーゲン産生促進作用、MMP1阻害作用及び活性酸素消去作用を持ち、安定性・効率性においても優れていることを見出した。さらに、その抽出物を含有する外用剤又は内用剤が安全で安定であり、且つテネイシンC発現促進作用、コラーゲン産生促進作用、MMP1阻害作用及び活性酸素消去作用に優れており、多機能性美容・健康用素材・医薬品と成り得ることを見出し、本発明を完成するに至った。 Under these circumstances, as a result of diligent studies by the present inventors, the extract of the buds of the genus Lily of the Liliaceae family, which has undergone dry heat treatment, has an excellent tenascin C expression promoting action, collagen production promoting action, MMP1 inhibitory action, and It was found that it has an active oxygen scavenging effect and is excellent in stability and efficiency. Furthermore, the external or internal preparation containing the extract is safe and stable, and is excellent in tenascin C expression promoting action, collagen production promoting action, MMP1 inhibitory action and active oxygen scavenging action, and is multifunctional beauty. -We have found that it can be used as a material for health and a pharmaceutical product, and have completed the present invention.
本発明の乾式加熱処理を行ったユリ科ユリ属の蕾部の抽出物は、優れたテネイシンC発現促進作用、コラーゲン産生促進作用、MMP1阻害作用及び活性酸素消去作用を有しており、医薬品、医薬部外品、化粧品、食品等の分野において貢献できるものである。 The extract of the bud part of the genus Lily of the Liliaceae family subjected to the dry heat treatment of the present invention has an excellent tenascin C expression promoting action, collagen production promoting action, MMP1 inhibitory action and active oxygen scavenging action, and is a pharmaceutical product. It can contribute to the fields of quasi-drugs, cosmetics, foods, etc.
本発明で用いるユリ科(Liliaceae)ユリ属(Lilium)の植物の種は、特に限定されるものではなく、例えば、ヤマユリ(Lilium auratum)、オニユリ(Lilium lancifolium)、ハカタユリ(Lilium brownii)、イトハユリ(Lilium pumilum)、カノコユリ(Lilium speciosum)、オトメユリ(Lilium rubellum)、リーガル・リリー(Lilium regale)、クルマユリ(Lilium medeoloides)、イワトユリ(Lilium maculatum)、テッポウユリ(Lilium longiflorum)、コオニユリ(Lilium leichtlinii)、タカサゴユリ(Lilium formosanum)、ヒメユリ(Lilium concolor)、マドンナ・リリー(Lilium candidum)、タモトユリ(Lilium nobilissimum)、又はそれらユリ属植物の変種・交配種等を用いることもできる。これらのユリ属の植物には、アジアティック・ハイブリッド、ロンギフローラム・ハイブリッド、マルタゴン・ハイブリッド、トランペット・ハイブリッド、オリエンタル・ハイブリッド等、多くの栽培品種が知られており、これらの栽培品種のユリを用いてもよい。本発明においては、その効果のよさから、オリエンタル・ハイブリッドとして知られているカサブランカを用いることが好ましい。 The species of plants of the Lilyaceae lily genus used in the present invention are not particularly limited, and are, for example, lily lily lily lily lily lily lily lily lily lily brown lily (lilyium brownii). Lilyum plumilum, lily lily speciosum, lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily lily Lilyum formomam, Lilyum concolor, Madonna lily, Lilyum candium, Lilyum nobilissimum, or varieties / hybrids of these lily genus plants can also be used. Many cultivars are known for these lily plants, such as Asiantic hybrid, Longiflorum hybrid, Martagon hybrid, Trumpet hybrid, Oriental hybrid, etc., and the lilies of these cultivars are used. You may. In the present invention, it is preferable to use Casablanca, which is known as an oriental hybrid, because of its good effect.
ユリ科ユリ属の蕾部としては、その長径が1cm〜10cmの範囲のもので、未熟なものから開花に近づいた状態のものまで、いずれの時期のものも使用できるが、雄蕊や雌蕊が完全に包まれていて外部から見えない状態のものを使用するのが好ましい。それに加えて、その長径が2cm〜4cmの範囲のものを使用するのが、特に好ましい。又、使用する蕾部は生でも良いし、自然乾燥品や天日乾燥品等の乾燥品を使用することもできる。 The buds of the genus Lily of the Liliaceae family have a major axis of 1 cm to 10 cm, and can be used at any time from immature to near flowering, but stamens and pistils are complete. It is preferable to use the one that is wrapped in and cannot be seen from the outside. In addition, it is particularly preferable to use one having a major axis in the range of 2 cm to 4 cm. Further, the buds to be used may be raw, or dried products such as naturally dried products and sun-dried products may be used.
ユリ科ユリ属の蕾部の乾式加熱処理の温度は100℃以上が好ましく、120℃〜280℃がより好ましい。さらに、150℃〜250℃付近が特に好ましい。280℃以上では、植物の炭化が進みやすく、抽出に不向きである。乾式加熱処理の時間は、温度によっても異なるが10分以上が好ましく、15分〜60分がより好ましい。さらに、20分〜40分が特に好ましい。60分以上加熱すると、植物の炭化が進みやすく、抽出に不向きである。又、これらの処理の時間については、2回〜5回等回数を分けて行ってもよい。その際の合計時間は、前述の時間となることが好ましい。 The temperature of the dry heat treatment of the buds of the genus Lily of the Liliaceae family is preferably 100 ° C. or higher, more preferably 120 ° C. to 280 ° C. Further, the temperature around 150 ° C. to 250 ° C. is particularly preferable. At 280 ° C. or higher, carbonization of plants tends to proceed, which is unsuitable for extraction. The time of the dry heat treatment varies depending on the temperature, but is preferably 10 minutes or more, more preferably 15 to 60 minutes. Further, 20 to 40 minutes is particularly preferable. When heated for 60 minutes or more, carbonization of plants tends to proceed, which is unsuitable for extraction. Further, the time for these treatments may be divided into 2 to 5 times and the like. The total time at that time is preferably the above-mentioned time.
乾式加熱処理を施したユリ科ユリ属の蕾部の抽出方法は特に限定されず、例えば、加熱抽出したものであってもよいし、常温抽出したものであってもよい。又、抽出には、乾式加熱処理を施した蕾部をそのまま使用してもよく、乾燥、粉砕、細切等の処理を行ってもよい。 The method for extracting the buds of the genus Lily of the Liliaceae family, which has been subjected to a dry heat treatment, is not particularly limited, and may be, for example, heat-extracted or room-temperature extracted. Further, for the extraction, the buds that have been subjected to the dry heat treatment may be used as they are, or may be subjected to treatments such as drying, crushing, and shredding.
抽出方法は、特に限定されないが、水もしくは熱水、又は水と有機溶媒の混合溶媒を用い、撹拌又はカラム抽出する方法等により行うことができる。抽出溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール類(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコール等の極性溶媒がよく、特に好ましくは、水、エタノール、1,3−ブチレングリコール及びプロピレングリコールがよい。これらの溶媒は一種でも二種以上を混合して用いてもよい。特に好ましい抽出溶媒としては、水、又は水−エタノール系の混合極性溶媒が挙げられる。溶媒の使用量については、特に限定はなく、例えば乾式加熱処理を施したユリ科ユリ属の蕾部(乾燥重量)に対し、10倍以上、好ましくは20倍以上であればよいが、抽出後に濃縮を行ったり、単離したりする場合の操作の便宜上100倍以下であることが好ましい。又、抽出温度や時間は、用いる溶媒の種類や抽出時の圧力等によって適宜選択できる。 The extraction method is not particularly limited, but can be carried out by a method of stirring or column extraction using water or hot water, or a mixed solvent of water and an organic solvent. Examples of the extraction solvent include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.) and liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol, etc.). , Glycerin, etc.), Ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether, etc.) Etc.). Polar solvents such as water, lower alcohols and liquid polyhydric alcohols are preferred, and water, ethanol, 1,3-butylene glycol and propylene glycol are particularly preferred. These solvents may be used alone or in admixture of two or more. Particularly preferable extraction solvents include water and water-ethanol mixed polar solvents. The amount of the solvent used is not particularly limited, and may be, for example, 10 times or more, preferably 20 times or more, that of the buds (dry weight) of the genus Lily of the Liliaceae family that have been subjected to dry heat treatment, but after extraction. It is preferably 100 times or less for convenience of operation when concentrating or isolating. The extraction temperature and time can be appropriately selected depending on the type of solvent used, the pressure at the time of extraction, and the like.
上記抽出物は、抽出した溶液のまま用いてもよいが、必要に応じて、本発明の効果を奏する範囲で、濃縮(減圧濃縮、膜濃縮等による濃縮)、希釈、濾過、活性炭等による脱色、脱臭、エタノール沈殿等の処理を行ってから用いてもよい。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いてもよい。 The above extract may be used as it is in the extracted solution, but if necessary, concentration (concentration by vacuum concentration, membrane concentration, etc.), dilution, filtration, decolorization with activated carbon, etc. is performed within the range in which the effect of the present invention is exhibited. , Deodorization, ethanol precipitation, etc. may be performed before use. Further, the extracted solution may be subjected to treatments such as concentrated drying, spray drying, freeze drying and the like, and used as a dried product.
本発明は、上記抽出物をそのまま使用してもよく、抽出物の効果を損なわない範囲内で、化粧品、医薬部外品、医薬品又は食品等に用いられる成分である油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、金属石鹸、pH調整剤、防腐剤、香料、保湿剤、粉体、紫外線吸収剤、増粘剤、色素、酸化防止剤、美白剤、キレート剤、賦形剤、皮膜剤、甘味料、酸味料等の成分が含有されていてもよい。 In the present invention, the above-mentioned extract may be used as it is, and oils and fats, waxes, and carbonized components used in cosmetics, non-pharmaceutical products, pharmaceuticals, foods, etc., as long as the effects of the extracts are not impaired. Hydrogens, fatty acids, alcohols, esters, surfactants, metal soaps, pH regulators, preservatives, fragrances, moisturizers, powders, UV absorbers, thickeners, pigments, antioxidants, whitening agents , Chelating agents, excipients, filming agents, sweeteners, acidity agents and the like may be contained.
本発明は、化粧品、医薬部外品、医薬品、食品のいずれにも用いることができ、その剤形としては、例えば、化粧水、クリーム、乳液、ゲル剤、エアゾール剤、エッセンス、パック、洗浄剤、浴用剤、ファンデーション、打粉、口紅、軟膏、パップ剤、錠菓、カプセル剤、チョコレート、ガム、飴、飲料、散剤、顆粒剤、錠剤、糖衣錠剤、カプセル剤、シロップ剤、丸剤、懸濁剤、液剤、乳剤、坐剤、注射用溶液等が挙げられる。 The present invention can be used for any of cosmetics, non-pharmaceutical products, pharmaceuticals, and foods, and the dosage forms thereof include, for example, cosmetics, creams, emulsions, gels, aerosols, essences, packs, and cleaning agents. , Baths, foundations, dusting, lipsticks, ointments, poultices, tablets, capsules, chocolates, gums, candy, beverages, powders, granules, tablets, sugar-coated tablets, capsules, syrups, pills, suspensions Examples include agents, solutions, emulsions, suppositories, solutions for injection and the like.
外用の場合、本発明に用いる上記抽出物の含有量は、固形物に換算して0.0001重量%以上が好ましく、0.001重量%〜10重量%がより好ましい。さらに、0.01重量%〜5重量%が最も好ましい。0.0001重量%未満では十分な効果は望みにくい。10重量%を越えると、効果の増強は認められにくく不経済である。 In the case of external use, the content of the extract used in the present invention is preferably 0.0001% by weight or more, more preferably 0.001% by weight to 10% by weight in terms of solid matter. Further, 0.01% by weight to 5% by weight is most preferable. If it is less than 0.0001% by weight, it is difficult to expect a sufficient effect. If it exceeds 10% by weight, the enhancement of the effect is hardly recognized and it is uneconomical.
内用の場合、摂取量は年齢、体重、症状、治療効果、投与方法、処理時間等により異なる。通常、成人1人当たりの1日の摂取量としては、5mg以上が好ましく、10mg〜5gがより好ましい。さらに、20mg〜2gが最も好ましい。 For internal use, the intake varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, and the like. Usually, the daily intake per adult is preferably 5 mg or more, more preferably 10 mg to 5 g. Further, 20 mg to 2 g is most preferable.
次に本発明を詳細に説明するため、実施例として本発明に用いる抽出物の製造例、実験例及び処方例を挙げるが、本発明はこれに限定されるものではない。製造例に示す%とは重量%を、処方例に示す含有量の部とは重量部を示す。 Next, in order to explain the present invention in detail, examples of production, experiment, and formulation of the extract used in the present invention will be given as examples, but the present invention is not limited thereto. The% shown in the production example means% by weight, and the content part shown in the formulation example means a weight part.
乾式加熱処理を施したカサブランカの蕾部の抽出物を以下の製造例1〜製造例3のとおり製造した。比較製造例1〜比較製造例3においては、抽出材料には乾式加熱処理を施していないカサブランカの蕾部を用いた。 An extract of the buds of Casablanca that had been subjected to a dry heat treatment was produced as described in Production Examples 1 to 3 below. In Comparative Production Examples 1 to 3, the buds of Casablanca that had not been subjected to the dry heat treatment were used as the extraction material.
(製造例1)乾式加熱処理を施したカサブランカの蕾部の熱水抽出物の調製
カサブランカの蕾部(長径2cm〜4cmで雄蕊や雌蕊が外部から見えない生のもの(図1))をステンレス製のトレーに均一に並べ、送風下、200℃の温度で30分間乾式加熱処理を施した。乾式加熱処理を施したカサブランカの蕾部を粉砕し、粉砕物10gに200mLの水を加え、95℃〜100℃で2時間抽出した。得られた抽出液を濾過し、その濾液を濃縮し、凍結乾燥して乾式加熱処理を施したカサブランカの蕾部の熱水抽出物を2.8g得た。
(Manufacturing Example 1) Preparation of hot water extract of buds of Casablanca subjected to dry heat treatment Stainless steel buds of Casablanca (raw stamens and pistils with a major axis of 2 cm to 4 cm and no visible stamens or pistils from the outside (Fig. 1)) They were evenly arranged on a stainless steel tray and subjected to a dry heat treatment at a temperature of 200 ° C. for 30 minutes under ventilation. The buds of Casablanca subjected to the dry heat treatment were pulverized, 200 mL of water was added to 10 g of the pulverized product, and the mixture was extracted at 95 ° C to 100 ° C for 2 hours. The obtained extract was filtered, the filtrate was concentrated, freeze-dried, and subjected to dry heat treatment to obtain 2.8 g of a hot water extract of the buds of Casablanca.
(比較製造例1)乾式加熱処理を施していないカサブランカの蕾部の熱水抽出物の調製
製造例1において、乾式加熱処理を施したカサブランカの蕾部を、乾式加熱処理を施していないカサブランカの蕾部に置き換えて、熱水抽出物を2.6g得た。
(Comparative Production Example 1) Preparation of hot water extract of buds of Casablanca not subjected to dry heat treatment In Production Example 1, the buds of Casablanca subjected to dry heat treatment were prepared from Casablanca not subjected to dry heat treatment. Replacing with the buds, 2.6 g of hot water extract was obtained.
(製造例2)乾式加熱処理を施したカサブランカの蕾部の50%エタノール抽出物の調製
製造例1と同様に乾式加熱処理を施したカサブランカの蕾部を粉砕し、粉砕物10gに200mLの50%エタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、乾式加熱処理を施したカサブランカの蕾部の50%エタノール抽出物を1.7g得た。
(Production Example 2) Preparation of 50% ethanol extract of buds of Casablanca subjected to dry heat treatment The buds of Casablanca subjected to dry heat treatment were crushed in the same manner as in Production Example 1, and 200 mL of 50 was added to 10 g of the pulverized product. % Ethanol was added, and the mixture was extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness to obtain 1.7 g of 50% ethanol extract of the buds of Casablanca subjected to dry heat treatment.
(比較製造例2)乾式加熱処理を施していないカサブランカの蕾部の50%エタノール抽出物の調製
製造例2において、乾式加熱処理を施したカサブランカの蕾部を、乾式加熱処理を施していないカサブランカの蕾部に置き換えて、50%エタノール抽出物を1.6g得た。
(Comparative Production Example 2) Preparation of 50% ethanol extract of buds of Casablanca not subjected to dry heat treatment In Production Example 2, the buds of Casablanca subjected to dry heat treatment were subjected to Casablanca not subjected to dry heat treatment. In place of the buds, 1.6 g of 50% ethanol extract was obtained.
(製造例3)乾式加熱処理を施したカサブランカの蕾部のエタノール抽出物の調製
製造例1と同様に乾式加熱処理を施したカサブランカの蕾部を粉砕し、粉砕物10gに200mLのエタノールを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、乾式加熱処理を施したカサブランカの蕾部のエタノール抽出物を0.5g得た。
(Production Example 3) Preparation of ethanol extract of buds of Casablanca subjected to dry heat treatment The buds of Casablanca subjected to dry heat treatment were crushed in the same manner as in Production Example 1, and 200 mL of ethanol was added to 10 g of the pulverized product. After extraction at room temperature for 7 days, the mixture was filtered, and the filtrate was concentrated to dryness to obtain 0.5 g of an ethanol extract of the buds of Casablanca subjected to dry heat treatment.
(比較製造例3)乾式加熱処理を施していないカサブランカの蕾部のエタノール抽出物の調製
製造例3において、乾式加熱処理を施したカサブランカの蕾部を、乾式加熱処理を施していないカサブランカの蕾部に置き換えて、エタノール抽出物を0.4g得た。
(Comparative Production Example 3) Preparation of ethanol extract of buds of Casablanca not subjected to dry heat treatment In Production Example 3, the buds of Casablanca subjected to dry heat treatment are buds of Casablanca not subjected to dry heat treatment. Substituted for parts, 0.4 g of ethanol extract was obtained.
(処方例1) 化粧水
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)2.0
2.1,3−ブチレングリコール 8.0
3.グリセリン 2.0
4.キサンタンガム 0.02
5.クエン酸 0.01
6.クエン酸ナトリウム 0.1
7.エタノール 5.0
8.パラオキシ安息香酸メチル 0.1
9.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
10.香料 適量
11.精製水にて全量を100とする
[製造方法]成分1〜6及び11と、成分7〜10をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
(Prescription example 1) Toner prescription content (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 2.0
2.1,3-butylene glycol 8.0
3. 3. Glycerin 2.0
4. Xanthan gum 0.02
5. Citric acid 0.01
6. Sodium citrate 0.1
7. Ethanol 5.0
8. Methyl paraoxybenzoate 0.1
9. Polyoxyethylene hydrogenated castor oil (40EO) 0.1
10. Appropriate amount of fragrance 11. [Manufacturing method]
比較処方例1 従来の化粧水
処方例1において、乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)を精製水に置き換えたものを従来の化粧水とした。
Comparative Formulation Example 1 Conventional Toner In Formulation Example 1, the hot water extract (Production Example 1) of the buds of Casablanca that had been subjected to dry heat treatment was replaced with purified water to obtain the conventional lotion.
(処方例2) クリーム
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の
50%エタノール抽出物(製造例2) 1.0
2.スクワラン 5.5
3.オリーブ油 3.0
4.ステアリン酸 2.0
5.ミツロウ 2.0
6.ミリスチン酸オクチルドデシル 3.5
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ベヘニルアルコール 1.5
9.モノステアリン酸グリセリン 2.5
10.香料 0.1
11.パラオキシ安息香酸メチル 0.2
12.1,3−ブチレングリコール 8.5
13.精製水にて全量を100とする
[製造方法]成分2〜9を加熱溶解して混合し、70℃に保ち油相とする。成分1及び11〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分10を加え、さらに30℃まで冷却して製品とする。
(Prescription example 2) Cream prescription content (part)
1. 1. The buds of Casablanca that have undergone dry heat treatment
50% ethanol extract (Production Example 2) 1.0
2. Squalene 5.5
3. 3. Olive oil 3.0
4. Stearic acid 2.0
5. Beeswax 2.0
6. Octyldodecyl myristate 3.5
7. Polyoxyethylene cetyl ether (20EO) 3.0
8. Behenyl alcohol 1.5
9. Glycerin monostearate 2.5
10. Fragrance 0.1
11. Methyl paraoxybenzoate 0.2
12.1,3-butylene glycol 8.5
13. [Manufacturing method] Ingredients 2 to 9 having a total amount of 100 in purified water are melted by heating and mixed, and kept at 70 ° C. to prepare an oil phase.
(処方例3) 乳液
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の
エタノール抽出物(製造例3) 0.01
2.スクワラン 5.0
3.オリーブ油 5.0
4.ホホバ油 5.0
5.セタノール 1.5
6.モノステアリン酸グリセリン 2.0
7.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
8.ポリオキシエチレンソルビタンモノオレエート(20E.O.) 2.0
9.香料 0.1
10.プロピレングリコール 1.0
11.グリセリン 2.0
12.パラオキシ安息香酸メチル 0.2
13.精製水にて全量を100とする
[製造方法]成分1〜8を加熱溶解して混合し、70℃に保ち油相とする。成分10〜13を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分9を加え、さらに30℃まで冷却して製品とする。
(Prescription example 3) Emulsion prescription content (part)
1. 1. The buds of Casablanca that have undergone dry heat treatment
Ethanol extract (Production Example 3) 0.01
2. Squalene 5.0
3. 3. Olive oil 5.0
4. Jojoba oil 5.0
5. Cetanol 1.5
6. Glycerin monostearate 2.0
7. Polyoxyethylene cetyl ether (20EO) 3.0
8. Polyoxyethylene sorbitan monooleate (20EO) 2.0
9. Fragrance 0.1
10. Propylene glycol 1.0
11. Glycerin 2.0
12. Methyl paraoxybenzoate 0.2
13. [Manufacturing method]
(処方例4) ゲル剤
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)1.0
2.エタノール 5.0
3.パラオキシ安息香酸メチル 0.1
4.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
5.香料 適量
6.1,3−ブチレングリコール 5.0
7.グリセリン 5.0
8.キサンタンガム 0.1
9.カルボキシビニルポリマー 0.2
10.水酸化カリウム 0.2
11.精製水にて全量を100とする
[製造方法]成分2〜5と、成分1及び6〜11をそれぞれ均一に溶解し、両者を混合して製品とする。
(Prescription example 4) Gel preparation Prescription content (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 1.0
2. Ethanol 5.0
3. 3. Methyl paraoxybenzoate 0.1
4. Polyoxyethylene hydrogenated castor oil (60EO) 0.1
5. Appropriate amount of fragrance 6.1,3-butylene glycol 5.0
7. Glycerin 5.0
8. Xanthan gum 0.1
9. Carboxyvinyl polymer 0.2
10. Potassium hydroxide 0.2
11. [Manufacturing method] Ingredients 2 to 5 and
(処方例5) パック
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の
50%エタノール抽出物(製造例2) 2.0
2.ポリビニルアルコール 12.0
3.エタノール 5.0
4.1,3−ブチレングリコール 8.0
5.パラオキシ安息香酸メチル 0.2
6.ポリオキシエチレン硬化ヒマシ油(20E.O.) 0.5
7.クエン酸 0.1
8.クエン酸ナトリウム 0.3
9.香料 適量
10.精製水にて全量を100とする
[製造方法]成分1〜10を均一に溶解し製品とする。
(Prescription example 5) Pack prescription content (part)
1. 1. The buds of Casablanca that have undergone dry heat treatment
50% ethanol extract (Production Example 2) 2.0
2. Polyvinyl alcohol 12.0
3. 3. Ethanol 5.0
4.1,3-butylene glycol 8.0
5. Methyl paraoxybenzoate 0.2
6. Polyoxyethylene hydrogenated castor oil (20EO) 0.5
7. Citric acid 0.1
8. Sodium citrate 0.3
9. Appropriate amount of fragrance 10. [Manufacturing method]
(処方例6) ファンデーション
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の
エタノール抽出物(製造例3) 1.0
2.ステアリン酸 2.4
3.ポリオキシエチレンソルビタンモノステアレート(20E.O.) 1.0
4.ポリオキシエチレンセチルエーテル(20E.O.) 2.0
5.セタノール 1.0
6.液状ラノリン 2.0
7.流動パラフィン 3.0
8.ミリスチン酸イソプロピル 6.5
9.カルボキシメチルセルロースナトリウム 0.1
10.ベントナイト 0.5
11.プロピレングリコール 4.0
12.トリエタノールアミン 1.1
13.パラオキシ安息香酸メチル 0.2
14.二酸化チタン 8.0
15.タルク 4.0
16.ベンガラ 1.0
17.黄酸化鉄 2.0
18.香料 適量
19.精製水にて全量を100とする
[製造方法]成分1〜8を加熱溶解し、80℃に保ち油相とする。成分19に成分9をよく膨潤させ、続いて、成分10〜13を加えて均一に混合する。これに粉砕機で粉砕混合した成分14〜17を加え、ホモミキサーで撹拌し75℃に保ち水相とする。油相に水相をかき混ぜながら加え、乳化する。その後、冷却し、45℃で成分18を加え、かき混ぜながら30℃まで冷却して製品とする。
(Prescription example 6) Foundation prescription content (part)
1. 1. The buds of Casablanca that have undergone dry heat treatment
Ethanol extract (Production Example 3) 1.0
2. Stearic acid 2.4
3. 3. Polyoxyethylene sorbitan monostearate (20EO) 1.0
4. Polyoxyethylene cetyl ether (20EO) 2.0
5. Cetanol 1.0
6. Liquid lanolin 2.0
7. Liquid paraffin 3.0
8. Isopropyl myristate 6.5
9. Sodium Carboxymethyl Cellulose 0.1
10. Bentonite 0.5
11. Propylene glycol 4.0
12. Triethanolamine 1.1
13. Methyl paraoxybenzoate 0.2
14. Titanium dioxide 8.0
15. Talc 4.0
16. Bengala 1.0
17. Yellow iron oxide 2.0
18. Appropriate amount of fragrance 19. [Manufacturing method]
(処方例7) 浴用剤
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)1.0
2.炭酸水素ナトリウム 50.0
3.黄色202号(1) 適量
4.香料 適量
5.硫酸ナトリウムにて全量を100とする
[製造方法]成分1〜5を均一に混合し製品とする。
(Prescription example 7) Prescription content for bath (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 1.0
2. Sodium bicarbonate 50.0
3. 3. Yellow No. 202 (1) Appropriate amount 4. Appropriate amount of fragrance 5. [Manufacturing method]
(処方例8) 軟膏
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の
50%エタノール抽出物(製造例2) 6.0
2.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
3.モノステアリン酸グリセリン 10.0
4.流動パラフィン 5.0
5.セタノール 6.0
6.パラオキシ安息香酸メチル 0.1
7.プロピレングリコール 10.0
8.精製水にて全量を100とする
[製造方法]成分1〜5を加熱溶解して混合し、70℃に保ち油相とする。成分6〜8を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
(Prescription example 8) Ointment prescription content (part)
1. 1. The buds of Casablanca that have undergone dry heat treatment
50% ethanol extract (Production Example 2) 6.0
2. Polyoxyethylene cetyl ether (30EO) 2.0
3. 3. Glycerin monostearate 10.0
4. Liquid paraffin 5.0
5. Cetanol 6.0
6. Methyl paraoxybenzoate 0.1
7. Propylene glycol 10.0
8. [Manufacturing method]
(処方例9) 散剤
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)1.0
2.乾燥コーンスターチ 39.0
3.微結晶セルロース 60.0
[製造方法]成分1〜3を混合し、散剤とする。
(Prescription example 9) Powder formulation Prescription content (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 1.0
2. Dried cornstarch 39.0
3. 3. Microcrystalline Cellulose 60.0
[Manufacturing method]
(処方例10) 錠剤
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)5.0
2.乾燥コーンスターチ 25.0
3.カルボキシメチルセルロースカルシウム 20.0
4.微結晶セルロース 40.0
5.ポリビニルピロリドン 7.0
6.タルク 3.0
[製造方法]成分1〜4を混合し、次いで成分5の水溶液を結合剤として加えて顆粒成型する。成型した顆粒に成分6を加えて打錠する。1錠0.52gとする。
(Prescription example 10) Tablet prescription content (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 5.0
2. Dried cornstarch 25.0
3. 3. Carboxymethyl Cellulose Calcium 20.0
4. Microcrystalline Cellulose 40.0
5. Polyvinylpyrrolidone 7.0
6. Talc 3.0
[Manufacturing method]
(処方例11) 錠菓
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)2.0
2.乾燥コーンスターチ 49.8
3.エリスリトール 40.0
4.クエン酸 5.0
5.ショ糖脂肪酸エステル 3.0
6.香料 0.1
7.精製水にて全量を100とする
[製造方法]成分1〜4及び7を混合し、顆粒成型する。成型した顆粒に成分5及び6を加えて打錠する。1粒1.0gとする。
(Prescription example 11) Tablet confectionery prescription content (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 2.0
2. Dried cornstarch 49.8
3. 3. Erythritol 40.0
4. Citric acid 5.0
5. Sucrose fatty acid ester 3.0
6. Fragrance 0.1
7. Set the total amount to 100 with purified water
[Manufacturing method]
(処方例12) 飲料
処方 含有量(部)
1.乾式加熱処理を施したカサブランカの蕾部の熱水抽出物(製造例1)0.05
2.ステビア 0.05
3.リンゴ酸 5.0
4.香料 0.1
5.精製水にて全量を100とする
[製造方法]成分1〜3を少量の水に溶解する。次いで、成分4及び5を加えて混合する。
(Prescription example 12) Beverage prescription content (part)
1. 1. Hot water extract of buds of Casablanca subjected to dry heat treatment (Production Example 1) 0.05
2. Stevia 0.05
3. 3. Malic acid 5.0
4. Fragrance 0.1
5. [Manufacturing method]
次に、本発明の効果を詳細に説明するため、実験例を挙げる。 Next, in order to explain the effect of the present invention in detail, an experimental example will be given.
実験例1 ヒト皮膚線維芽細胞におけるテネイシンC、I型コラーゲン及びマトリックス分解酵素産生に及ぼす乾式加熱処理を施したカサブランカの蕾部の抽出物の影響
テネイシンC(TNC)、I型コラーゲン(COL1A1)及びマトリックス分解酵素(MMP1)mRNA発現量の測定を行った。ヒト皮膚線維芽細胞(NB1RGB)を60mm dishに1×105個播種し、10%FBSを含むDMEM培養液にて、37℃、5%CO2条件下で培養した。コンフルエントな状態になったところで、PBS(−)存在下、3日連続でUVA 10J/cm2を照射した。照射後は、DMEM(+)の培地に置き換え、各試料を最終濃度で10μg/mL及び100μg/mLとなるように添加した。最終照射から24時間培養した後、RNAiso plus(タカラバイオ)を用いて総RNAの抽出を行った。総RNA量は分光光度計(NanoDrop)を用いて260nmにおける吸光度により求めた。mRNA発現量の測定は、細胞から抽出した総RNAを基にしてリアルタイムRT−PCR法により行った。リアルタイムRT−PCR法には、High Capacity RNA−to−cDNA Kit(Applied Biosystems)及びSYBR Select Master Mix(Applied Biosystems)を用いた。即ち、500ngの総RNAを逆転写反応後、PCR反応(95℃:15秒間、60℃:60秒間、40cycles)を行った。その他の操作は定められた方法に従い、TNC、COL1A1及びMMP1 mRNAの発現量を、内部標準であるβ―actin mRNAの発現量に対する割合として求めた。TNC、COL1A1及びMMP1発現率は、コントロール群のTNC、COL1A1及びMMP1 mRNAの発現量に対する試料添加群のTNC、COL1A1及びMMP1 mRNAの発現量の比率として算出した。尚、各遺伝子の発現量の測定に使用したプライマーは次の通りである。
Experimental Example 1 Effect of dry heat-treated Casablanca bud extract on the production of tenascin C, type I collagen and matrix-degrading enzyme in human skin fibroblasts Tenascin C (TNC), type I collagen (COL1A1) and The expression level of matrix degrading enzyme (MMP1) mRNA was measured. Human skin fibroblasts (NB1RGB) were seeded in 1 × 10 5 cells on a 60 mm dish and cultured in DMEM culture medium containing 10% FBS under 37 ° C. and 5% CO 2 conditions. When the condition became confluent, UVA 10 J / cm 2 was irradiated for 3 consecutive days in the presence of PBS (-). After irradiation, the medium was replaced with DMEM (+) medium, and each sample was added to a final concentration of 10 μg / mL and 100 μg / mL. After culturing for 24 hours after the final irradiation, total RNA was extracted using RNAiso plus (Takara Bio). The total amount of RNA was determined by the absorbance at 260 nm using a spectrophotometer (NanoDrop). The mRNA expression level was measured by the real-time RT-PCR method based on the total RNA extracted from the cells. For the real-time RT-PCR method, High Capacity RNA-to- cDNA Kit (Applied Biosystems) and SYBR Select Master Mix (Applied Biosystems) were used. That is, after a reverse transcription reaction of 500 ng of total RNA, a PCR reaction (95 ° C: 15 seconds, 60 ° C: 60 seconds, 40 cycles) was performed. For other operations, the expression levels of TNC, COL1A1 and MMP1 mRNA were determined as a ratio to the expression level of β-actin mRNA, which is an internal standard, according to a predetermined method. The expression rates of TNC, COL1A1 and MMP1 were calculated as the ratio of the expression levels of TNC, COL1A1 and MMP1 mRNA in the sample addition group to the expression levels of TNC, COL1A1 and MMP1 mRNA in the control group. The primers used to measure the expression level of each gene are as follows.
TNC用のプライマーセット
CTCCACAGCCAAAGAACC(配列番号1)
CACAGTCTCCAGCAACCT(配列番号2)
COL1A1用のプライマーセット
AGGACAAGAGGCATGTCTGGTT(配列番号3)
TTGCAGTGGTAGGTGATGTTCTG(配列番号4)
MMP1用のプライマーセット
GGGAGATCATCGGGACAACTC(配列番号5)
TGAGCATCCCCTCCAATACC(配列番号6)
β-actin用のプライマーセット
CACTCTTCCAGCCTTCCTTCC(配列番号7)
GTGTTGGCGTACAGGTCTTTG(配列番号8)
Primer set for TNC CTCCAGAGCCAAAGAACC (SEQ ID NO: 1)
CAAGTCTCCAGCAACCT (SEQ ID NO: 2)
Primer set for COL1A1 AGGACAAGAGGCATGTCTGGTT (SEQ ID NO: 3)
TTGCAGTGGTAGGTGATGTTTCTG (SEQ ID NO: 4)
Primer set for MMP1 GGGAGATCATCGGGACAACTC (SEQ ID NO: 5)
TGAGCATCCCCCTCCAAATACC (SEQ ID NO: 6)
Primer set for β-actin CACTCTTCCAGCCTTCCTCC (SEQ ID NO: 7)
GTGTTGGGCGTACAGGTCTTG (SEQ ID NO: 8)
その結果を表1〜3に示した。尚、表中の「コントロール」はUVA未照射且つ試料を添加していない群、「UVA」はUVA照射後に試料を添加していない群を意味する。UVAを連続照射するとTNC及びCOL1A1 mRNA発現量が減少したが、カサブランカの蕾部の抽出物はその減少を抑制した。その効果は、乾式加熱処理を施していないカサブランカの抽出物と比較して乾式加熱処理を施したカサブランカの抽出物の方が顕著に高かった。又、UVAを連続照射するとMMP1 mRNA発現量が増加したが、カサブランカの蕾部の抽出物はその増加を抑制した。その効果は、乾式加熱処理を施していないカサブランカの抽出物と比較して乾式加熱処理を施したカサブランカの抽出物の方が顕著に高かった。 The results are shown in Tables 1 to 3. In the table, "control" means a group in which UVA is not irradiated and no sample is added, and "UVA" means a group in which no sample is added after UVA irradiation. Continuous irradiation with UVA reduced the expression levels of TNC and COL1A1 mRNA, but the extract of the buds of Casablanca suppressed the decrease. The effect was significantly higher in the Casablanca extract subjected to the dry heat treatment than in the Casablanca extract not subjected to the dry heat treatment. In addition, continuous irradiation with UVA increased the expression level of MMP1 mRNA, but the extract of the buds of Casablanca suppressed the increase. The effect was significantly higher in the Casablanca extract subjected to the dry heat treatment than in the Casablanca extract not subjected to the dry heat treatment.
実験例2 乾式加熱処理を施したカサブランカの蕾部の熱水抽出物の活性酸素消去作用
上記の実施例で得られた、乾式加熱処理を施したカサブランカの蕾部の抽出物について、Superoxide dismutase(SOD)様活性をSOD Assay Kit−WST(同仁化学研究所)を用い、96ウェルプレートにて測定した。試薬は、キットに付属のものを用いた。各ウェルに、試料液20μLを加えた後、WST working solutionを200μL加え、プレートミキサーでよく撹拌した。ブランクのウェルにはDilution bufferを20μL加えた。試料液を加えたウェルとブランクのウェルとにそれぞれEnzyme working solutionを20μL加えた。その後、37℃で20分間インキュベートし、プレートリーダーで450nmにおける吸光度を測定した。各抽出液の活性酸素消去率50%時の濃度(μg/mL)をIC50値として求めた。
Experimental Example 2 Active oxygen scavenging action of hot water extract of buds of Casablanca subjected to dry heat treatment Superoxide dismutase (Superoxide dismutase) of the extract of buds of Casablanca subjected to dry heat treatment obtained in the above example. SOD) -like activity was measured on a 96-well plate using SOD Assay Kit-WST (Dojin Chemical Laboratory). The reagent used was that included in the kit. After adding 20 μL of the sample solution to each well, 200 μL of WST working solution was added, and the mixture was well stirred with a plate mixer. 20 μL of Dilution buffer was added to the blank wells. 20 μL of Enzyme working solution was added to each of the well to which the sample solution was added and the well to which the sample solution was added. Then, the mixture was incubated at 37 ° C. for 20 minutes, and the absorbance at 450 nm was measured with a plate reader. The concentration (μg / mL) of each extract at an active oxygen scavenging rate of 50% was determined as an IC 50 value.
各試料の試験結果から、50%のスーパーオキシドの除去に必要とされる濃度(IC50)を算出した。より低いIC50値が、より強力な活性酸素消去剤を意味する。これらの試験結果を表4に示した。本発明の乾式加熱処理を施したカサブランカの蕾部の抽出物は安定で優れたSOD様活性を示した。又、乾式加熱処理を施したカサブランカの蕾部の抽出物は、乾式加熱処理を施していないカサブランカの蕾部の抽出物と比較して、顕著に優れたSOD様活性を有していることが認められた。以上のことから、乾式加熱処理によって、カサブランカの蕾部の抽出物のSOD様活性が顕著に増加することが認められた。 From the test results of each sample, the concentration (IC 50 ) required for the removal of 50% superoxide was calculated. Lower an IC 50 value is meant more potent active oxygen scavenger. The results of these tests are shown in Table 4. The extract of the buds of Casablanca subjected to the dry heat treatment of the present invention showed stable and excellent SOD-like activity. Further, the extract of the buds of Casablanca subjected to the dry heat treatment has significantly superior SOD-like activity as compared with the extract of the buds of Casablanca not subjected to the dry heat treatment. Admitted. From the above, it was confirmed that the SOD-like activity of the extract of the buds of Casablanca was remarkably increased by the dry heat treatment.
実験例3 使用試験
処方例1の化粧水及び比較処方例1の従来の化粧水を用いて、シワ、たるみがある5人(26〜64才)を対象に1ヶ月間の使用試験を行った。使用後、シワ、たるみの程度をアンケートにより判定した。
Experimental Example 3 Use test Using the lotion of Prescription Example 1 and the conventional lotion of Comparative Prescription Example 1, a one-month use test was conducted on 5 people (26-64 years old) with wrinkles and sagging. .. After use, the degree of wrinkles and sagging was judged by a questionnaire.
その結果、本発明の抽出物を含有する皮膚外用剤により、シワ、たるみが軽減した。尚、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。又、処方成分の劣化についても問題なかった。 As a result, wrinkles and sagging were alleviated by the external preparation for skin containing the extract of the present invention. During the test period, there were no skin problems and there was no problem in terms of safety. In addition, there was no problem with deterioration of the formulated ingredients.
以上のことから、本発明の乾式加熱処理を施したユリ科ユリ属の蕾部の抽出物は、優れたTNC発現促進作用、コラーゲン産生促進作用、MMP1阻害作用及び活性酸素消去作用を有し、安定性にも優れていた。このことから、本発明の乾式加熱処理を施したユリ科ユリ属の蕾部の抽出物は、皮膚の老化といった美容分野だけでなく、老化による機能低下の抑制、ガンの予防、治療等といった医療分野にも利用でき、食品、化粧品、医薬部外品及び医薬品等への応用が期待される。 From the above, the extract of the bud of the genus Lily of the Liliaceae family subjected to the dry heat treatment of the present invention has an excellent TNC expression promoting action, collagen production promoting action, MMP1 inhibitory action and active oxygen scavenging action. It was also excellent in stability. From this, the extract of the bud part of the genus Lily of the Liliaceae family, which has been subjected to the dry heat treatment of the present invention, is used not only in the cosmetic field such as skin aging, but also in medical treatment such as suppression of functional deterioration due to aging, prevention and treatment of cancer. It can also be used in the field, and is expected to be applied to foods, cosmetics, quasi-drugs, pharmaceuticals, etc.
Claims (8)
An internal preparation containing an extract of a bud of the genus Lily of the Liliaceae family, which has been subjected to a dry heat treatment.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019228336A JP7433628B2 (en) | 2019-12-18 | 2019-12-18 | Skin external preparations and internal preparations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019228336A JP7433628B2 (en) | 2019-12-18 | 2019-12-18 | Skin external preparations and internal preparations |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021095371A true JP2021095371A (en) | 2021-06-24 |
JP7433628B2 JP7433628B2 (en) | 2024-02-20 |
Family
ID=76430525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019228336A Active JP7433628B2 (en) | 2019-12-18 | 2019-12-18 | Skin external preparations and internal preparations |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7433628B2 (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2940612B1 (en) | 2008-12-30 | 2011-05-06 | Oreal | ASSOCIATION OF MONOSACCHARIDES WITH ASCORBIC ACID AND ITS USE IN COSMETICS |
JP5698586B2 (en) | 2010-04-01 | 2015-04-08 | 共栄化学工業株式会社 | Cosmetics |
-
2019
- 2019-12-18 JP JP2019228336A patent/JP7433628B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP7433628B2 (en) | 2024-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5138262B2 (en) | Topical skin preparation | |
JP6247847B2 (en) | Skin wrinkle formation preventive / improving agent, hyaluronic acid production promoter, collagen production promoter and MMP inhibitor | |
JP2020158424A (en) | External or internal skin preparations | |
JP5144362B2 (en) | Topical skin preparation | |
JP7148115B2 (en) | Collagen production promoter, MMP inhibitor, melanogenesis inhibitor, cell proliferation promoter, antioxidant, wrinkle improving agent, pharmaceutical or food composition | |
JP2008280249A (en) | Skin-lightening cosmetic | |
JP7433628B2 (en) | Skin external preparations and internal preparations | |
JP5366358B2 (en) | Agent for acting on skin aging mechanism, anti-aging skin external preparation, and anti-aging method | |
JP2021095343A (en) | Active oxygen scavenger, collagen production promoter, hyaluronic acid production promoter, wrinkle improver, pharmaceutical, or internal preparation | |
JP6281761B2 (en) | External preparation or internal preparation containing Hidakami Sebaya extract | |
JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
JP7389465B2 (en) | Melanin production inhibitor, collagen production promoter and antioxidant | |
JP5690149B2 (en) | External preparation or internal preparation | |
JP7278564B2 (en) | Hyaluronic Acid Production Promoter, Collagen Production Promoter, MMP Inhibitor, Wrinkle Improving Agent, Pharmaceutical or Food Composition | |
JP5468866B2 (en) | Topical skin preparation | |
JP5415216B2 (en) | Topical skin preparation | |
JP2022022526A (en) | External preparation and internal preparation for skin | |
JP2021080212A (en) | Cell proliferation promoter, mmp-2 inhibitor, topical skin preparation, pharmaceutical and internal preparation | |
JP2022024329A (en) | Melanin production inhibitor, collagen production promoter, hyaluronic acid production promoter, mmp-2 inhibitor, and internal agent | |
JP2022034789A (en) | External and internal skin agents | |
JP2023077751A (en) | Collagen production promoter, MMP inhibitor, cell proliferation promoter and internal agent | |
JP6646534B2 (en) | Basic fibroblast growth factor production promoter | |
JP2022189261A (en) | Collagen production promoter, MMP inhibitor, hyaluronic acid production promoter and internal agent | |
JP2023007747A (en) | Mmp inhibitors, enhancers for hyaluronic acid production and internal preparations | |
JP2024041161A (en) | External preparation and internal preparation for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221031 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230927 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231220 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240123 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240131 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7433628 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |